November 2013 More than half of heroin-addicted patients treated with naltrexone via an implanted delivery device maintained abstinence throughout a 6-month clinical trial in Saint Petersburg, Russia. The implant device, which releases a steady dose of naltrexone continuously for 2 months, averted relapse to heroin use three times as effectively as daily oral doses of the medication.
February 2013 Despite the advances in treatment and prevention, roughly 50,000 new HIV infections still occur annually in the Nation. Research, in large part supported by NIDA, has produced a strategy to address this circumstance and break the epidemiological impasse: seek out HIV-infected individuals, particularly those in “hard-to-reach” groups that have minimal contact with the health care system; offer them HIV testing and treatment; and provide support to help them stay in treatment.
Reports finding from a study showing that access to antiretroviral therapies, HAART in particular, can improve the health of HIV-infected patients who have a history of injection drug use.
June 2008 Highlights the NIDA International Program which works to strengthen international research networks, creating opportunities for global research collaboration, training, and scientific exchange.